Dan Pettitt is Vice President, Market Access, Immunology for the Global Commercial Strategy Organization, Janssen Global Services. He is responsible for developing product access strategies and corresponding evidence generation programs to optimize utilization and revenue. For more than seven years, Dan and the Immunology Access team have successfully secured access and exceeded time to reimbursement metrics for STELARA® (ustekinumab), SIMPONI® (golimumab), and TREMFYA® (guselkumab) in multiple indications.
Prior to working at Janssen, Dan spent 15 years in market access and reimbursement at Bristol Meyers Squibb (BMS), Pfizer, and Amgen. While working at BMS, Dan led access and health economic activities for three top-selling drugs. After BMS, Dan led reimbursement activities for ten years at Pfizer and helped his organization to win multiple U.S. managed care best partner awards. Dan was also a key contributor to a real-world evidence generation program that was able to successfully differentiate the company’s lead anti-inflammatory treatment from its competitor to prevent license removal.
Dan’s professional objectives and career aspirations have played a key role in developing viable business models and strategies that will endure as healthcare systems evolve globally. He has a strong background in commercial, clinical development, evidence-based medicine, epidemiology, and health economic disciplines. In addition, he has extensive relationships with academia and an impactful academic publication history.
Dan earned his MBA from Columbia University and a M.S. in Epidemiology and D.V.M. from the University of Guelph.
Follow Dan on LinkedIn here.